Citation:Macbeth FR, Bolger JJ, Hopwood P, Bleehen NM, Cartmell J, Girling DJ, et al 1996

Citation

Macbeth FR, Bolger JJ, Hopwood P, Bleehen NM, Cartmell J, Girling DJ, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol) 1996;8(3):167-75 Available from: http://www.ncbi.nlm.nih.gov/pubmed/8814371.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Macbeth FR, Bolger JJ, Hopwood P, Bleehen NM, Cartmell J, Girling DJ, et al 1996	What is the clinical benefit of radiotherapy to the lung primary in stage IV NSCLC?	Associate Professor Shalini Vinod MBBS MD FRANZCR	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the clinical benefit of radiotherapy to the lung primary in Stage IV NSCLC?|]] (compare critical appraisals)

Cited by

1. Emma.dickins/Sandbox
2. What is the clinical benefit of radiotherapy to the lung primary in stage IV NSCLC?
3. What is the optimal treatment approach for patients with stage III inoperable NSCLC who, because of patient or tumour factors, are not suitable for curative treatment with concurrent chemo-radiotherapy and who do not have a mutation for targeted therapy?